This item was written by my colleague Anita Banicevic While most consumers know that their clicks and “likes” leave a digital trail, the rise of the digital economy has led to a spike in the volume and types of data being created and collected. If data is “the new oil,” it’s no surprise that regulators…
The following item was prepared by my colleagues Jim Dinning and David Feldman In the annual Davies forecast of the year ahead for Canadian competition law, we discuss the top five issues and trends to watch for in Canadian competition law this year. 1. New Leadership at the Bureau and a Year of Transition 2018…
Introduction On December 18 2017, the Authority for Consumers and Markets (the ACM) announced that it had halted its investigation into cartel agreements between Dutch and German towage companies in various ports in Germany and the Netherlands. Stek represented one of the German towage companies in this investigation. The ACM’s decision to stop the investigation…
The German Federal Cartel Office (‘FCO’) decided in 2015 that ASICS, the manufacturer of sports and running shoes, may not prevent its dealers from cooperating with price comparison engines. The German Federal Court of Justice (‘BGH’) has now, in a judgment published on 19 January 2018, confirmed the FCO’s decision. The judgment comes only weeks…
On 23 January 2018, Germany’s Federal Supreme Court (Bundesgerichtshof – BGH) handed down its judgment on allegedly anti-competitive requests for preferential rebates and conditions by food retailers (case KVR 3/17 – not yet published). This is an important judgment as it removes a major roadblock to antitrust enforcement in the food retail sector in Germany,…
As authorities worldwide step up enforcement of their merger control rules, companies planning deals in 2018 must pay even closer attention to their obligations and conduct throughout the period from early planning up to final merger control clearance. We are seeing more authorities impose heavy fines for an increasingly wide range of pre-clearance conduct, with…
This case relates to the interplay between EU competition law and the pharmaceutical regulatory regime. It arose in the context of an arrangement in which Genentech licensed Bevacizumab to one company in the field of Ophthalmology (‘Lucentis’) and to another company for the treatment of cancers (‘Avastin’). There was a delay in obtaining an MA…
The European Commission’s recent focus on the impact of mergers on innovation competition has sparked a heated debate amongst lawyers and economists. Innovation seems to have become the new “Greater Good” the Commission is pursuing when reviewing mergers, whether in the pharmaceutical or medical device sectors, in pesticides, engineering, ICT or other technology-driven industries. The…
On 19 December 2017 the Federal Administrative Court issued three judgments reversing the sanctions against the producers Pfizer, Eli Lilly and Bayer imposed by the Competition Commission which totaled in CHF 5.7 million. The court concludes that the non-binding price recommendations published by the three pharmaceutical companies did not restrict competition but rather prevented excessive…
Most merger control regimes provide for so-called stand-still obligations, i.e. the parties cannot implement the transaction until the necessary merger clearances have been received from the relevant competition authorities. This means in particular that the acquiring company cannot starting controlling the target’s business prior to closing – no “gun jumping” is allowed. Competition authorities have…
